UGP2 and colorectal carcinoma: We propose that in CRC, the loss of UGP2 may provide a selective advantage to cancer cells not primarily by disrupting glycogen storage but possibly by altering the availability of UDP-glucose for other essential processes, such as the glycosylation of important membrane receptors or the hexosamine biosynthesis pathway.